Positive on Britannia, GSK Consumer: Ajay Bodke

Ajay Bodke of Prabhudas Lilladher told CNBC-TV18, "In the FMCG space, there are two scripts we are very positive on, the first is Britannia Industries. The company has seen a sharp sort of a fall from its peak couple of months back because of concerns of some raw materials prices having moved up from the bottom. The company has unveiled a plan to ensure that the margins do not get impacted. They are moving up the value chain, increasing their distribution network quite aggressively especially in the Northern and Eastern belt where they have a limited presence as compared to the Southern and the Western belt. We believe that they will be able to tide over the increase in the raw materials and hence we believe that in one year perspective, the stock should do extremely well, a target price of Rs 3,200 with a medium-term perspective.""GlaxoSmithKline Consumer Healthcare is another company where we are positive. Here although the volume growth will remain tepid, in case of Horlicks it will be better than last quarter because last quarter the floods in Tamil Nadu has impacted the volume growth. Also the company’s Managing Director in media interaction said that they will be laying a lot of emphasis on some of the over-the-counter (OTC) products. Globally they are very strong in some of the OTC products which they will be launching and the distribution will done by the listed entity. So, these are two names that we are very positive on," he said.